Profectus and Path Malaria Vaccine Initiative Enter Research Collaboration

September 9, 2009

Profectus BioSciences, Inc. (Baltimore, MD), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates for serious chronic infections, has signed a research collaboration agreement with the PATH Malaria Vaccine Initiative (Bethesda, MD) to conduct proof-of-concept studies with its proprietary, recombinant vesicular stomatitis virus (rVSV) vector technology as a preventative malaria vaccine.

Profectus BioSciences, Inc. (Baltimore, MD), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates for serious chronic infections, has signed a research collaboration agreement with the PATH Malaria Vaccine Initiative (Bethesda, MD) to conduct proof-of-concept studies with its proprietary, recombinant vesicular stomatitis virus (rVSV) vector technology as a preventative malaria vaccine.

Profectus has two key vaccine vector platforms, plasmid DNA and rVSV, which can be sequentially administered in a prime-boost regimen to elicit a potent and durable immune response to target pathogens. Each of these vectors alone is capable of inducing a strong immune response. Furthermore, when these vectors are sequentially used in a prime-boost regimen, immune responses of significantly greater magnitude and quality are generated. This approach represents a significant advancement in vaccine development as compared to historical DNA vaccines and adenovirus-based vectors.